Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae200 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2025. Verfasst von Karie Runcie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology New York Presbyterian Hospital, New York, NY 10032, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Oncolytic Virotherapy, Carcinoma, Pancreatic Ductal, Biological Products. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, FDA HHS, NCI.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) presents a redoubtable challenge due to late-stage diagnosis and limited treatment options, necessitating innovative therapeutic strategies.
Methods
Here, we report our results investigating the safety and efficacy of talimogene laherparepvec (T-VEC), an FDA-approved oncolytic herpes simplex virus type 1, in patients with advanced PDAC. Nine patients with treatment-refractory advanced PDAC received escalating doses of T-VEC via endoscopic injection.
Results
While no objective responses were observed, stable disease was achieved in 44% of patients, with a median overall survival of 7.8 months, including one patient who survived 28 months. Adverse events were manageable, with the maximum tolerated dose determined to be 108 PFU/mL.
Conclusion
Our findings underscore the feasibility of intratumoral T-VEC administration in advanced PDAC. Further investigation, particularly in combination with immunotherapies administered systemically is warranted to more optimally assess T-VEC in this challenging malignancy. ClinicalTrials.gov Identifier: NCT03086642.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology New York Presbyterian Hospital, New York, NY 10032, United States.
- Department of Oncology Albert Einstein College of Medicine, Bronx, NY 10461, United States.
- Department of Anatomic Pathology, New York Presbyterian Hospital, New York, NY 10032, United States.
- NYU Grossman School of Medicine, New York, NY 10016, United States.
ORCID-Profile: Karie Runcie, Yadriel Bracero, Yvonne Saenger
Förderung
- NCI NIH HHS
- FDA HHS
- NCI
Zitieren
APA
Runcie, K., Bracero, Y., Samouha, A., Manji, G., Remotti, H. E., Gonda, T. A., & Saenger, Y. (2025). Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae200
Vancouver
Runcie K, Bracero Y, Samouha A, Manji G, Remotti HE, Gonda TA, et al. Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyae200
BibTeX
@article{Runcie2025,
author = {Runcie, Karie and Bracero, Yadriel and Samouha, Avishai and Manji, Gulam and Remotti, Helen E and Gonda, Tamas A and Saenger, Yvonne},
title = {Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae200}
}
EUVIMED